Therapeutic Focus
Infirmacea outlines its therapeutic focus and exploratory disease areas where its DNA medicine platform may address high treatment burden and long-term therapy needs.
Exploratory Disease Areas Aligned with Our Platform
Infirmacea’s therapeutic focus reflects areas where our safe and accessible DNA medicine platform may be particularly well suited. These areas are presented for strategic and illustrative purposes.
Selection Criteria
We prioritize disease contexts characterized by:
• Need for long-term or lifelong therapy
• Reliance on repeated protein administration
• High treatment burden or adherence challenges
• Heightened safety sensitivity, including pediatric populations
Exploratory Focus Areas
Adult Growth Hormone Deficiency (GHD)
A lifelong endocrine condition typically managed with frequent injections over many years.
Hypoparathyroidism (hypoPT)
A rare endocrine disorder characterized by insufficient parathyroid hormone production
Functional Hypothalamic Amenorrhea (FHA)
Absence of menstrual periods for three or more months because physical or emotional stress suppresses the brain’s hormone signals that control ovulation
Anorexia Nervosa (AN)
A serious disorder associated with profound metabolic and hormonal disruption, with limited treatment options.
Obesity
A chronic, progressive disease characterized by excessive body fat accumulation that presents a serious risk to health
For general background of these diseases, please visit Resouce page.
Partnerships
Infirmacea seeks strategic collaborations to explore and advance potential applications of its platform. We welcome discussions with partners interested in pediatric therapeutics, protein biology, and non-viral gene expression technologies.
Disclaimer
Disease areas listed are exploratory and presented for illustrative purposes only. No therapeutic claims are made.